NCT00425802View on ClinicalTrials.gov

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 28, 2006

Primary Completion Date

October 28, 2016

Study Completion Date

October 28, 2016

Conditions

LeukemiaLymphoma

Interventions

BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

filgrastim

BIOLOGICAL

graft-versus-tumor induction therapy

BIOLOGICAL

rituximab

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

fludarabine phosphate

DRUG

mycophenolate mofetil

PROCEDURE

nonmyeloablative allogeneic hematopoietic stem cell transplantation

RADIATION

total-body irradiation

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00425802 - Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter